Answers are grounded in this paper and cite their sources.
Simultaneous binding to the catalytic and peripheral sites of acetylcholinesterase (AChE) is invoked to explain why the new drug (S,S)-(−)-3, in which two aminoquinolinone units are linked by a dodecamethylene tether, is more than twice as potent as the natural product huperzine A (−)-1 in the inhibition of AChE. In contrast aminoquinolinone (±)-2, which retains much of the functionality of (−)-1, inhibits AChE only very weakly.
No takes yet. Share an insight, caveat, or question.
Carlier et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: